organization · Reporting owner
Takeda Pharmaceuticals International AG
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Molecular Templates, Inc.MTEM · Entity 85987 | 10% owner | August 01, 2017 | September 08, 2017 |
| Myovant Sciences Ltd.MYOV · Entity 115677 | 10% owner | March 19, 2018 | March 21, 2018 |
| Quince Therapeutics, Inc.CRTX · Entity 7403 | 10% owner | May 13, 2019 | May 13, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Molecular Templates, Inc.
Report date August 01, 2017 · Filed September 08, 2017
Jointly reported with MILLENNIUM PHARMACEUTICALS INC, Takeda Pharma A/S, Takeda A/S, Takeda Europe Holdings B.V., TAKEDA PHARMACEUTICAL CO LTD, Takeda Pharmaceuticals U.S.A., Inc.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,922,993 |
Reported balance
Holding disclosure · report date 2017-08-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,922,993 F1: These shares are owned directly by Millennium Pharmaceuticals, Inc. ("Millennium"). Millennium is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceutical Company Limited ("Takeda") owns 73.37% of Takeda USA, and Takeda Pharmaceuticals International AG ("Takeda International") owns 26.63% of Takeda USA. Takeda Pharma A/S ("Takeda Denmark") owns 86.83% of Takeda International, and Takeda Europe Holdings B.V. ("Takeda Europe") owns 13.17% of Takeda International. Takeda Denmark is a wholly-owned direct subsidiary of Takeda A/S. Takeda owns 76.09% of Takeda A/S, and Takeda Europe owns 23.91% of Takeda A/S. Takeda Europe is a wholly-owned direct subsidiary of Takeda. Takeda, Takeda USA, Takeda International, Takeda Denmark, Takeda A/S and Takeda Europe each disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are owned directly by Millennium Pharmaceuticals, Inc. ("Millennium"). Millennium is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceutical Company Limited ("Takeda") owns 73.37% of Takeda USA, and Takeda Pharmaceuticals International AG ("Takeda International") owns 26.63% of Takeda USA. Takeda Pharma A/S ("Takeda Denmark") owns 86.83% of Takeda International, and Takeda Europe Holdings B.V. ("Takeda Europe") owns 13.17% of Takeda International. Takeda Denmark is a wholly-owned direct subsidiary of Takeda A/S. Takeda owns 76.09% of Takeda A/S, and Takeda Europe owns 23.91% of Takeda A/S. Takeda Europe is a wholly-owned direct subsidiary of Takeda. Takeda, Takeda USA, Takeda International, Takeda Denmark, Takeda A/S and Takeda Europe each disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein.
Myovant Sciences Ltd.
Report date March 19, 2018 · Filed March 21, 2018
Jointly reported with TAKEDA PHARMACEUTICAL CO LTD, Takeda A/S, Takeda Europe Holdings B.V., Takeda Pharma A/S
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-03-19 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-03-19 · Sale · Disposed 7,420,625 · Balance 0 F1: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Millennium Pharmaceuticals , Inc. | 7,420,625 |
Reported balance
After 2018-03-19 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-03-19 · Purchase · Acquired 7,420,625 · Balance 7,420,625 F1: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC.
F2: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein.
Quince Therapeutics, Inc.
Report date May 13, 2019 · Filed May 13, 2019
Jointly reported with Takeda Ventures, Inc., TAKEDA PHARMACEUTICAL CO LTD, Takeda Pharmaceuticals U.S.A., Inc.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,679,802 |
Reported balance
After 2019-05-13 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-05-13 · Conversion · Acquired 2,679,802 · Balance 2,679,802 F1: The total represents shares received upon conversion of shares of Series A Redeemable Convertible Preferred Stock and shares of Series B Redeemable Convertible Preferred Stock. F2: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F3: These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited. |
| Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-05-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-05-13 · Conversion · Disposed 2,360,071 · Balance 0 F2: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F3: These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited. |
| Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-05-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-05-13 · Conversion · Disposed 319,731 · Balance 0 F2: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F3: These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited. |
Filing footnotes · ownership attribution and instrument terms
F1: The total represents shares received upon conversion of shares of Series A Redeemable Convertible Preferred Stock and shares of Series B Redeemable Convertible Preferred Stock.
F2: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.
F3: These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2019 Filed May 13, 2019 19:52 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 319,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029480 · doc4.xml · derivative · entry 3 Takeda Ventures, Inc. · CIK 0001771657 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner Takeda Pharmaceuticals U.S.A., Inc. · CIK 0001716229 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 319,731 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F3 · ownership.direct: These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited. Read SEC document |
| May 13, 2019 Filed May 13, 2019 19:52 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | ConversionSeries A Redeemable Convertible Preferred Stock · Derivative | 2,360,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029480 · doc4.xml · derivative · entry 2 Takeda Ventures, Inc. · CIK 0001771657 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner Takeda Pharmaceuticals U.S.A., Inc. · CIK 0001716229 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,360,071 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F3 · ownership.direct: These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited. Read SEC document |
| May 13, 2019 Filed May 13, 2019 19:52 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | ConversionCommon Stock | 2,679,802 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-029480 · doc4.xml · nonDerivative · entry 1 Takeda Ventures, Inc. · CIK 0001771657 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner Takeda Pharmaceuticals U.S.A., Inc. · CIK 0001716229 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,679,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The total represents shares received upon conversion of shares of Series A Redeemable Convertible Preferred Stock and shares of Series B Redeemable Convertible Preferred Stock. F2 · price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F3 · ownership.direct: These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 21:42 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 7,420,625 | $18.67 | $138,543,068.75 |
DisclosureSEC source: 0000899243-18-008309 · doc4.xml · nonDerivative · entry 2 Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Takeda A/S · CIK 0001716380 · 10% owner Takeda Europe Holdings B.V. · CIK 0001716379 · 10% owner Takeda Pharma A/S · CIK 0001716226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Millennium Pharmaceuticals , Inc. Disclosed balance after: 7,420,625 F1 · acquired: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2 · acquired: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein. F1 · balance_after: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2 · balance_after: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein. F1 · ownership.nature: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2 · ownership.nature: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 21:42 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Stock | 7,420,625 | $18.67 | $138,543,068.75 |
DisclosureSEC source: 0000899243-18-008309 · doc4.xml · nonDerivative · entry 1 Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Takeda A/S · CIK 0001716380 · 10% owner Takeda Europe Holdings B.V. · CIK 0001716379 · 10% owner Takeda Pharma A/S · CIK 0001716226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · acquired: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2 · acquired: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein. F1 · balance_after: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2 · balance_after: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 16:12 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionWarrant to Purchase Common Shares · Derivative | 4,432 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-027447 · doc4.xml · derivative · entry 2 Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 4,432 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: $0.000017727 per share. F2 · derivative.exercise_date: At any time following the Issuer's issuance of any class of capital shares, if necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership in the Issuer, as determined after such exercise. F3 · derivative.expiration_date: Upon the earlier of (A) April 30, 2017 and (B) a change of control of the Issuer, unless such change in control results in a privately-held entity in which the holders of 40% or more of the equity securities, calculated on a fully-diluted basis, of the surviving entity are held by persons and entities who were affiliates of the Issuer prior to such change in control. F4 · balance_after: An indeterminate number of capital shares necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership interest in the Issuer, as determined after such exercise. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 16:12 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 4,432 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-027447 · doc4.xml · nonDerivative · entry 1 Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,420,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: $0.000017727 per share. Read SEC document |
| March 15, 2017 Filed Mar 24, 2017 18:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionWarrant to Purchase Common Shares · Derivative | 13,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-022833 · doc4.xml · derivative · entry 4 Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 13,091 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: $0.000017727 per share. F2 · derivative.exercise_date: At any time following the Issuer's issuance of any class of capital shares, if necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership in the Issuer, as determined after such exercise. F3 · derivative.expiration_date: Upon the earlier of (A) April 30, 2017 and (B) a change of control of the Issuer, unless such change in control results in a privately-held entity in which the holders of 40% or more of the equity securities, calculated on a fully-diluted basis, of the surviving entity are held by persons and entities who were affiliates of the Issuer prior to such change in control. F4 · balance_after: An indeterminate number of capital shares necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership interest in the Issuer, as determined after such exercise. Read SEC document |
| March 15, 2017 Filed Mar 24, 2017 18:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 13,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-022833 · doc4.xml · nonDerivative · entry 2 Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,416,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: $0.000017727 per share. Read SEC document |
| February 15, 2017 Filed Mar 24, 2017 18:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionWarrant to Purchase Common Shares · Derivative | 6,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-022833 · doc4.xml · derivative · entry 3 Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,845 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: $0.000017727 per share. F2 · derivative.exercise_date: At any time following the Issuer's issuance of any class of capital shares, if necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership in the Issuer, as determined after such exercise. F3 · derivative.expiration_date: Upon the earlier of (A) April 30, 2017 and (B) a change of control of the Issuer, unless such change in control results in a privately-held entity in which the holders of 40% or more of the equity securities, calculated on a fully-diluted basis, of the surviving entity are held by persons and entities who were affiliates of the Issuer prior to such change in control. F4 · balance_after: An indeterminate number of capital shares necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership interest in the Issuer, as determined after such exercise. Read SEC document |
| February 15, 2017 Filed Mar 24, 2017 18:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 6,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-022833 · doc4.xml · nonDerivative · entry 1 Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,403,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: $0.000017727 per share. Read SEC document |
| January 17, 2017 Filed Mar 13, 2017 16:34 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionWarrant to Purchase Common Shares · Derivative | 5,727 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-17-000243 · edgar.xml · derivative · entry 4 Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,727 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: $0.000017727 per share. F2 · derivative.exercise_date: At any time following the Issuer's issuance of any class of capital shares, if necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership in the Issuer, as determined after such exercise. F3 · derivative.expiration_date: Upon the earlier of (A) April 30, 2017 and (B) a change of control of the Issuer, unless such change in control results in a privately-held entity in which the holders of 40% or more of the equity securities, calculated on a fully-diluted basis, of the surviving entity are held by persons and entities who were affiliates of the Issuer prior to such change in control. F4 · balance_after: An indeterminate number of capital shares necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership interest in the Issuer, as determined after such exercise. Read SEC document |
| January 17, 2017 Filed Mar 13, 2017 16:34 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 5,727 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-17-000243 · edgar.xml · nonDerivative · entry 2 Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,396,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: $0.000017727 per share. Read SEC document |
| December 15, 2016 Filed Mar 13, 2017 16:34 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionWarrant to Purchase Common Shares · Derivative | 22,141 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-17-000243 · edgar.xml · derivative · entry 3 Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 22,141 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: $0.000017727 per share. F2 · derivative.exercise_date: At any time following the Issuer's issuance of any class of capital shares, if necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership in the Issuer, as determined after such exercise. F3 · derivative.expiration_date: Upon the earlier of (A) April 30, 2017 and (B) a change of control of the Issuer, unless such change in control results in a privately-held entity in which the holders of 40% or more of the equity securities, calculated on a fully-diluted basis, of the surviving entity are held by persons and entities who were affiliates of the Issuer prior to such change in control. F4 · balance_after: An indeterminate number of capital shares necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership interest in the Issuer, as determined after such exercise. Read SEC document |
| December 15, 2016 Filed Mar 13, 2017 16:34 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 22,141 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-17-000243 · edgar.xml · nonDerivative · entry 1 Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,390,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: $0.000017727 per share. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 16:49 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionWarrant to Purchase Common Shares · Derivative | 1,977,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-148209 · doc4.xml · derivative · entry 2 Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,977,269 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: $0.000017727 per share. F2 · derivative.exercise_date: At any time following the Issuer's issuance of any class of capital shares, if necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership in the Issuer, as determined after such exercise. F3 · derivative.expiration_date: Upon the earlier of (A) April 30, 2017 and (B) a change of control of the Issuer, unless such change in control results in a privately-held entity in which the holders of 40% or more of the equity securities, calculated on a fully-diluted basis, of the surviving entity are held by persons and entities who were affiliates of the Issuer prior to such change in control. F4 · balance_after: An indeterminate number of capital shares necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership interest in the Issuer, as determined after such exercise. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 16:49 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 1,977,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-148209 · doc4.xml · nonDerivative · entry 1 Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,368,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: $0.000017727 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.